Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
24 9월 2015 - 11:00PM
What:
Benitec Biopharma Ltd. (ASX:BLT) (Nasdaq:BNTC),
an Australian biotechnology company engaged in the development of
gene-silencing therapies for the treatment of chronic and
life-threatening diseases, will visit the Nasdaq MarketSite in
Times Square to celebrate its recent initial public offering
(IPO).
In honor of the occasion, Peter French, Chief Executive
Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Friday, September 25, 2015 – 9:15 a.m. to 9:30 a.m. ET
Benitec Biopharma Limited Media Contact:Andrew
Mielach Tiberend Strategic Advisors, Inc. (212) 375-2694
amielach@tiberend.com
Nasdaq MarketSite: Hilary Edelstein (646)
678-2321 Hilary.Edelstein@nasdaq.com
Feed Information: Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page:
http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Opening Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Benitec Biopharma
Limited (Nasdaq:BNTC):
Benitec Biopharma Limited (ASX:BLT) (NASDAQ:BNTCW) (NASDAQ:BNTC)
is a clinical-stage biotechnology company developing innovative
therapeutics based on its patented gene-silencing technology called
ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in
Hayward, CA (USA) and collaborators and licensees around the world,
the company is developing ddRNAi-based therapeutics for chronic and
life-threatening human conditions including hepatitis C and B, wet
age-related macular degeneration and OPMD. Benitec has also
licensed ddRNAi to other biopharmaceutical companies for
applications including HIV/AIDS, Huntington's Disease, chronic
neuropathic pain and retinitis pigmentosa. For further information
regarding Benitec and its activities, please contact the persons
below, or visit the Benitec website at www.benitec.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,600 listed companies
with a market value of approximately $9.6 trillion and more than
10,000 corporate clients. To learn more, visit: nasdaq.com/ambition
or business.nasdaq.com.
-NDAQA-
Benitec Biopharma (NASDAQ:BNTCW)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Benitec Biopharma (NASDAQ:BNTCW)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
